These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 23436617)

  • 1. Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes.
    Hirayama M; Nishikawa H; Nagata Y; Tsuji T; Kato T; Kageyama S; Ueda S; Sugiyama D; Hori S; Sakaguchi S; Ritter G; Old LJ; Gnjatic S; Shiku H
    Eur J Immunol; 2013 Apr; 43(4):989-1000. PubMed ID: 23436617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma.
    Nicholaou T; Ebert LM; Davis ID; McArthur GA; Jackson H; Dimopoulos N; Tan B; Maraskovsky E; Miloradovic L; Hopkins W; Pan L; Venhaus R; Hoffman EW; Chen W; Cebon J
    Clin Cancer Res; 2009 Mar; 15(6):2166-73. PubMed ID: 19276262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.
    Huarte E; Karbach J; Gnjatic S; Bender A; Jäger D; Arand M; Atanackovic D; Skipper J; Ritter G; Chen YT; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2004 Dec; 4():15. PubMed ID: 15600300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
    Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
    Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD4+Foxp3+ regulatory T cells converted by rapamycin from peripheral CD4+CD25(-) naive T cells display more potent regulatory ability in vitro.
    Chen JF; Gao J; Zhang D; Wang ZH; Zhu JY
    Chin Med J (Engl); 2010 Apr; 123(7):942-8. PubMed ID: 20497692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells.
    Yan B; Ye S; Chen G; Kuang M; Shen N; Chen S
    Arthritis Rheum; 2008 Mar; 58(3):801-12. PubMed ID: 18311820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
    Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF
    Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.
    Berntsen A; Brimnes MK; thor Straten P; Svane IM
    J Immunother; 2010 May; 33(4):425-34. PubMed ID: 20386464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definition of key variables for the induction of optimal NY-ESO-1-specific T cells in HLA transgene mice.
    Johannsen A; Genolet R; Legler DF; Luther SA; Luescher IF
    J Immunol; 2010 Sep; 185(6):3445-55. PubMed ID: 20733200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination.
    Nishikawa H; Qian F; Tsuji T; Ritter G; Old LJ; Gnjatic S; Odunsi K
    J Immunol; 2006 May; 176(10):6340-6. PubMed ID: 16670346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downregulation of CD4+CD25+ regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells.
    Cao Q; Wang L; Du F; Sheng H; Zhang Y; Wu J; Shen B; Shen T; Zhang J; Li D; Li N
    Cell Res; 2007 Jul; 17(7):627-37. PubMed ID: 17563757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
    Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
    Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.
    Wang DW; Zhou RB; Yao YM; Zhu XM; Yin YM; Zhao GJ; Dong N; Sheng ZY
    J Pharmacol Exp Ther; 2010 Dec; 335(3):553-61. PubMed ID: 20843956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.
    Redjimi N; Duperrier-Amouriaux K; Raimbaud I; Luescher I; Dojcinovic D; Classe JM; Berton-Rigaud D; Frenel JS; Bourbouloux E; Valmori D; Ayyoub M
    PLoS One; 2011; 6(7):e22845. PubMed ID: 21829534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex-vivo expanded baboon CD4+ CD25 Hi Treg cells suppress baboon anti-pig T and B cell immune response.
    Singh AK; Seavey CN; Horvath KA; Mohiuddin MM
    Xenotransplantation; 2012; 19(2):102-11. PubMed ID: 22497512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432.
    Aoki M; Ueda S; Nishikawa H; Kitano S; Hirayama M; Ikeda H; Toyoda H; Tanaka K; Kanai M; Takabayashi A; Imai H; Shiraishi T; Sato E; Wada H; Nakayama E; Takei Y; Katayama N; Shiku H; Kageyama S
    Vaccine; 2009 Nov; 27(49):6854-61. PubMed ID: 19761832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.
    Ayyoub M; Souleimanian NE; Godefroy E; Scotto L; Hesdorffer CS; Old LJ; Valmori D
    Clin Immunol; 2006; 118(2-3):188-94. PubMed ID: 16368270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
    Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S
    Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Function of CD4+,CD25+ Treg cells in MRL/lpr mice is compromised by intrinsic defects in antigen-presenting cells and effector T cells.
    Parietti V; Monneaux F; Décossas M; Muller S
    Arthritis Rheum; 2008 Jun; 58(6):1751-61. PubMed ID: 18512811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The significantly enhanced frequency of functional CD4+CD25+Foxp3+ T regulatory cells in therapeutic dose aspirin-treated mice.
    Javeed A; Zhang B; Qu Y; Zhang A; Sun C; Zhang L; Liu J; Zeng C; Zhao Y
    Transpl Immunol; 2009 Mar; 20(4):253-60. PubMed ID: 19146957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.